Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $410.6 million.

  • Ultragenyx Pharmaceutical's Total Non-Current Liabilities rose 1569.71% to $410.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $410.6 million, marking a year-over-year increase of 1569.71%. This contributed to the annual value of $421.3 million for FY2024, which is 1926.58% up from last year.
  • Ultragenyx Pharmaceutical's Total Non-Current Liabilities amounted to $410.6 million in Q3 2025, which was up 1569.71% from $365.2 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Total Non-Current Liabilities ranged from a high of $421.3 million in Q4 2024 and a low of $196.2 million during Q2 2021
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Total Non-Current Liabilities value was $317.5 million (recorded in 2022), while the average stood at $305.9 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Total Non-Current Liabilities crashed by 3304.81% in 2021 and then soared by 4452.75% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Total Non-Current Liabilities (Quarter) stood at $248.0 million in 2021, then increased by 28.0% to $317.5 million in 2022, then increased by 11.26% to $353.3 million in 2023, then rose by 19.27% to $421.3 million in 2024, then dropped by 2.56% to $410.6 million in 2025.
  • Its Total Non-Current Liabilities stands at $410.6 million for Q3 2025, versus $365.2 million for Q2 2025 and $366.6 million for Q1 2025.